Effects of encapsulation of primidone on its oxidative metabolism in rats

Drug Metabolism and Drug Interactions

Volumn 18, Issue 3-4, 2001, Pages 191-208

  Ferranti, V ^a   Chabenat, C ^a   Marchais, H ^a   Menager S ^a   Hue, H ^a   Orecchioni, A M ^a   Lafont, O ^a  

^a Laboratoire de Pharmacochimie   (France)

Author keywords

Nanocapsules; P hydroxyphenobarbital; Phenobarbital; Phenylethylmalonamide; Primidone metabolism

Indexed keywords

4' HYDROXYPHENOBARBITAL; ANTICONVULSIVE AGENT; CARBOXYMETHYLCELLULOSE; DRUG METABOLITE; ETHYL(PHENYL)MALONAMIDE; NANOCAPSULE; PHENOBARBITAL; POLYCAPROLACTONE; PRIMIDONE;

ANIMAL MODEL; ANTICONVULSANT THERAPY; ARTICLE; CONTROLLED STUDY; DRUG HALF LIFE; DRUG METABOLISM; DRUG RELEASE; ENCAPSULATION; EPILEPSY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; NONHUMAN; RAT; SCANNING ELECTRON MICROSCOPY; URINARY EXCRETION;

EID: 0035669566     PISSN: 07925077     EISSN: None     Source Type: Journal    
DOI: 10.1515/DMDI.2001.18.3-4.191     Document Type: Article

References (22)

1. Teratogenicity of antiepileptic drugs: Is the prevention possible?
2. Developmental toxicity of antiepileptic drugs: Relationship to postnatal dysfunction
3. Studies on the intracerebral metabolism of anticonvulsant drugs - I. Perfusion of primidone through the isolated brain of the rat
4. Sensitive analytical method for serum primidone and its active metabolites for single dose. Pharmacokinetic analysis in human subjects
5. Phenylethylmalonamide (PEMA). An important metabolite of primidone
6. New chemical aspects of primidone metabolism
7. Teratogenic effects associated with maternal primidone therapy
8. Primidone-induced embryo lethality and DRL in surviving offspring
9. Congenital malformations due to antiepileptic drugs
10. Developmental and behavioral effects of prenatal primidone exposure in the rat
11. Blood and cerebrospinal fluid pharmacokinetics of primidone and its primary pharmacologically active metabolites, phenobarbital and phenylethylmalonamide in the rat
12. Vectorisation et vecteurs de médicaments
13. Design of new formulations for typical ocular administration: Polymeric nanocapsules containing metipranolol
14. The oral absorption of micro- and nanoparticulates: Neither exceptional nor unusual
15. Effect of a selected suppression of the reticuloendothelial system on the distribution of model carrier particles
16. Physiologically based pharmacokinetics model of primidone and its metabolites phenobarbital and phenylethylmalonamide in humans, rats and mice
17. GC-MS determination of phenobarbitone entrapped in poly-ε-caprolactone nanocapsules
18. Entrapment efficiency and initial release of phenylbutazone from nanocapsules prepared from different polyesters
19. Primidone-loaded poly-ε-caprolactone nanocapsules: Incorporation efficiency and in vitro release profiles
20. Simultaneous determination of primidone and its three major metabolites in rat urine by high-performance liquid chromatography using solid-phase extraction
21. Nanocapsule formation by interfacial deposition following solvent displacement
22. Clinical application of serum primidone levels